List of investigational hallucinogens and entactogens explained

This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. Many of the indications are not for continuous medication therapy but rather for medication-assisted psychotherapy or short-term use only. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Hallucinogens

Psychedelics

Dimethyltryptamine (DMT) – addiction, substance-related disorders – Entheon Biomedical https://www.newsfilecorp.com/release/75039/Entheon-Biomedical-Announces-Ethics-Approval-for-In-Vivo-DMT-Study
Lysergic acid diethylamide (LSD; "Lucy") – anxiety disorders, attention-deficit hyperactivity disorder, cluster headache, major depressive disorder – MAPS, MindMed https://adisinsight.springer.com/drugs/800058011 https://mindmed.co/news/press-release/mindmed-launches-project-lucy-focused-on-lsd-experiential-therapy-for-anxiety-disorders/ https://mindmed.co/news/press-release/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator/ https://maps.org/research/psilo-lsd
Psilocybin (COMP-360, PB-1818, PSY-0.1–0.6, MYCO-001) – bipolar depression, depressive disorders, major depressive disorder, somatoform disorders, post-traumatic stress disorders – COMPASS Pathways, PsyBio Therapeutics, Mydecine https://adisinsight.springer.com/drugs/800050861 https://adisinsight.springer.com/drugs/800058818 https://adisinsight.springer.com/drugs/800057550 https://adisinsight.springer.com/drugs/800059460 https://adisinsight.springer.com/drugs/800060245 https://adisinsight.springer.com/drugs/800061766 https://adisinsight.springer.com/drugs/800061306 https://www.benzinga.com/markets/cannabis/21/04/20528665/mydecine-unveils-four-psychedelic-drug-candidates

Dissociatives

Arketamine ((R)-ketamine; HR-071603) – depressive disorders – Jiangsu Hengrui Medicine https://adisinsight.springer.com/drugs/800056158
Esketamine ((S)-ketamine; PG061) – bipolar depression, depressive disorders – Celon Pharma https://adisinsight.springer.com/drugs/800051201
Ketamine (ELE-Ket+, R-107, SHX-001, PMI-100, PMI-150, SLS-002, TUR-002; Ereska) – major depressive disorder, suicidal ideation, cluster headaches – Eleusis, Douglas Pharmaceuticals, Shenox Pharmaceuticals, CCH Pharmaceuticals, Seelos Therapeutics https://adisinsight.springer.com/drugs/800061553 https://adisinsight.springer.com/drugs/800052333 https://adisinsight.springer.com/drugs/800053262 https://adisinsight.springer.com/drugs/800056086 https://adisinsight.springer.com/drugs/800015882

Others/mixed

Ibogaine – opioid-related disorders – ATAI Life Sciences/DemeRx https://adisinsight.springer.com/drugs/800057347
Zolunicant (18-Methoxycoronaridine; 18-MC; MM-110) – leishmaniasis, opioid-related disorders, substance-related disorders – MindMed https://adisinsight.springer.com/drugs/800012987

Entactogens

R(-)-Methylenedioxymetamfetamine (MM-402; R(-)-MDMA) – pervasive child development disorders – MindMed https://adisinsight.springer.com/drugs/800066028
Midomafetamine (MDMA; "Ecstasy") – post-traumatic stress disorders, mood disorders, substance-related disorders, social anxiety in autism – MAPS, MindMed https://adisinsight.springer.com/drugs/800056202 https://adisinsight.springer.com/drugs/800058845 https://maps.org/research/mdma/anxiety/autism
MYCO-002 – MDMA-like entactogen – Mydecine https://www.benzinga.com/markets/cannabis/21/04/20528665/mydecine-unveils-four-psychedelic-drug-candidates

Others/unsorted

Ketanserin – LSD neutralization – MindMed https://mindmed.co/news/press-release/mindmeds-lsd-neutralizer-study-begins/

Mixed

Lysergic acid diethylamide/midomafetamine (LSD/MDMA) – psychedelic-assisted psychotherapy – MindMed https://mindmed.co/news/press-release/mindmed-announces-first-ever-clinical-trial-combining-mdma-and-lsd/ https://clinicaltrials.gov/ct2/show/NCT04516902

See also

List of investigational drugs

External links